A trial investigating a novel drug plus the chemotherapy docetaxel failed to show a survival benefit in patients with previously treated locally advanced or metastatic non–small cell lung cancer.
The phase 3 CANOPY-2 trial failed to meet its main goal of improving overall survival in patients with locally advanced or metastatic non–small cell lung cancer whose disease progressed on or after prior platinum-based chemotherapy and treatment with PD-1/L1 inhibitor therapy, according to Novartis.
The trial was designed to assess the effectiveness of the novel interleukin-1β inhibitor ACZ885 (canakinumab) plus the chemotherapy docetaxel compared with placebo in this patient population.
“While results from the CANOPY-2 trial are not what we hoped for in patients with advanced or metastatic non-small cell lung cancer who have been treated with other lines of therapy, these data give us valuable insights into IL-1β inhibition,” said Novartis’ head of global drug development and chief medical officer Dr. John Tsai in a news release. “Ongoing phase 3 studies in non-small cell lung cancer continue, evaluating canakinumab in earlier treatment settings.”
Novartis noted in the release that full data from the study will be presented at a future medical meeting.
The ongoing phase 3 trials include the CANOPY-1 and CANOPY-A trial. The CANOPY-1 trial has enrolled 673 patients to measure the effect Keytruda (pembrolizumab) plus platinum-based doublet chemotherapy with or without ACZ885 has on overall survival and progression-free survival in previously untreated locally advanced or metastatic nonsquamous and squamous patients.
The CANOPY-A trial is actively recruiting patients, with a target enrollment of 1,500 individuals. The goal of the trial, according to Novartis, is to assess ACZ885’s effect on disease-free survival in patients with stage 2, stage 3a and certain stage 3b disease, compared to placebo.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.